



The changing landscape of cancer care

Thanks to innovations across the healthcare system, we have seen remarkable breakthroughs in cancer care and treatment. However, the rapid pace of change presents challenges for oncology care professionals working in both community and academic settings.

Innovation means nothing if it doesn’t reach the doctors and patients who need it most.

To better understand the challenges that healthcare professionals are facing when it comes to delivering the latest innovations to their patients, the J&J Oncology Care Index surveyed 500 oncologists, urologists, and Advanced Practice Providers (APPs) in the US.

Key findings at a glance

Oncologists are overwhelmed by the pace of change.

In 2024, more than 50 novel treatments were approved in the US, including 11 first-in-class therapeutics.¹



Nearly 3 out of 4

find the pace of new treatment development overwhelming.²



Around 7 out of 10

struggle to navigate the complexities of cancer treatment guidelines.²

The gap between innovation and implementation is widening.



73% say

there’s a gap between the availability of new/cutting-edge treatments and their successful implementation in clinical practice.²



92% agree

that Continuing Medical Education (CME) is crucial for providing cutting-edge treatments.²

Three key themes from the J&J Oncology Care Index

1. Smarter collaboration in a complex landscape



55%

of Americans battling cancer receive treatment in community oncology settings.³

This reinforces the crucial role played by community oncologists, whose practices can provide state-of-the-art, quality care in cancer clinics usually within a few miles of the patient’s home.



9 out of 10

HCPs are interested in knowledge-sharing programs, particularly MDs and APPs.²

APPs play a critical role in helping patients manage their disease throughout the treatment journey. APPs help navigate complexity and facilitate collaboration with multidisciplinary teams, leading to better outcomes for patients.

49%

of HCPs wish they could increase opportunities to collaborate with their counterparts in academic and community medical settings.²

>90%

of HCPs see APPs as crucial in improving continuity of care, reducing wait times, and enhancing patient satisfaction.²

Collaboration among oncologists, APPs, and other care team members is essential to bridge gaps, maintain continuity of care, and ensure patients remain at the center of everything they do.



Dr. Stephen Divers
Chief Medical Officer,
American Oncology Network

“ In oncology today, the challenge isn’t just the science, it’s the complexity. From navigating evolving guidelines to placing patients in clinical trials, the administrative burden is enormous. AI has the potential to help, not by making clinical decisions, but by simplifying the systems we rely on. Together, we can identify the solutions that keep patients at the center of care while maintaining quality in the community. ”

2. AI holds promise, but barriers to adoption remain



HCPs believe AI has decreased the time it takes to diagnose patients in oncology care by about 20%, on average.²




42%

say limited information about AI and how to use it is a barrier to implementation.²

Advancements in AI promise more personalized and accessible care, but to fully unlock its potential, we must address barriers like education, infrastructure, and trust.

3. Expanding access to innovation



91%

of HCPs agree that a patient’s proximity to care significantly influences their treatment decisions.²

Many patients face barriers to clinical trial participation due to geographic and logistical challenges or lack of awareness. Expanding access through modernized infrastructure, advanced technologies, and patient-centered outreach is key to ensuring every patient benefits from the latest advancements in cancer care.



7 out of 10

HCPs report that their practice does not offer a robust range of clinical trial options.²

Our commitment

Johnson & Johnson is committed to supporting healthcare professionals in oncology to help bridge the gap between innovation and implementation. Here are a few programs already underway:

Make It HAPPen™

A national campaign launched in partnership with the Advanced Practitioner Society for Hematology and Oncology (APSHO) that highlights the critical role APPs play across the continuum of care. This program supports APPs by providing resources to enhance knowledge-sharing and improve patient-centered care across community and academic settings.

Oncology clinical educators

We have established a dedicated team that works closely with oncology nurses and APPs in clinical practice to help provide support and resources around education on new therapies and administration and monitoring guidance.

Advancing AI/ML (machine learning)

J&J is leveraging AI/machine learning to identify and prioritize clinical trial sites with a high probability of enrolling patients.

Expanding clinical trials into community settings

We are exploring how our therapies could be safely administered in outpatient and community settings, potentially expanding access for patients who might not otherwise be able to participate in trials.

Support for the Clinical Trial Modernization Act

Johnson & Johnson supports the Clinical Trial Modernization Act, bipartisan legislation aimed at increasing access to clinical trials by removing cost and geographic barriers to patient participation.

About the survey

Johnson & Johnson partnered with The Harris Poll to survey 500 oncologists, urologists, and Advanced Practice Providers (APPs) in the U.S. age 18+ who are duly licensed, to better understand the challenges that healthcare professionals are facing when it comes to delivering the latest innovations to their patients.

Oncologists and APP oncologists were required to treat at least 1 patient with blood and 1 patient with solid-state tumor cancer, while urologists and APP urologists were required to treat at least 1 patient with solid-state tumor cancer. The survey was fielded from Nov. 21 to Dec. 13, 2024.

- Respondents included 381 MDs and 119 APPs.
- Respondents, on average, reported seeing 85 patients a week.

Respondents included those who work in academic and community practices and a mix of settings, with the majority in urban and suburban locations.

1. Novel drug approvals for 2024. U.S. Food and Drug Administration (FDA). <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024>. January 15, 2025. Accessed February 14, 2025.
2. Johnson & Johnson Oncology & The Harris Poll. About the Survey: This survey was conducted online within the United States by The Harris Poll on behalf of Johnson & Johnson Oncology, from November 21-December 13, 2024 among 500 adults age 18+ who are duly licensed and either hematologists/oncologists, urologists, APPs in hematology/oncology, or APPs in urology (MDs in Oncology (n=221), MDs in Urology (n=160), Advanced Practice Providers (APPs) in Oncology (n=102), and APPs in Urology (n=17)). Oncologists and APP oncologists treat at least 1 patient with blood and 1 patient with solid-state tumor cancer, while urologists and APP urologists treat at least 1 patient with solid state tumor cancer.
3. FACT Sheet: What is Community Oncology? Community Oncology Alliance. <https://communityoncology.org/wp-content/uploads/2017/08/What-is-Comm-Onc.pdf>. Accessed February 18, 2025.